<DOC>
	<DOCNO>NCT00079261</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , gemcitabine , work different way stop cancer cell divide stop grow die . Combining one chemotherapy drug may kill cancer cell . PURPOSE : This randomized phase II trial study give combination chemotherapy together gemcitabine see well work compare give combination chemotherapy alone treat patient previously untreated aggressive stage II , stage III , stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Cyclophosphamide , Doxorubicin , Vincristine , Prednisone With Without Gemcitabine Treating Patients With Previously Untreated Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare complete response rate ( confirm unconfirmed ) patient previously untreated aggressive non-Hodgkin 's lymphoma treat cyclophosphamide , doxorubicin , vincristine , prednisone v without gemcitabine . Secondary - Compare safety profile regimens patient . - Compare feasibility regimen , define proportion course give schedule , patient . - Compare freedom treatment failure patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord participate center , International Prognostic Index score ( 0-2 v 3-5 ) , histology ( B cell v T cell ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral IV prednisone day 1-5 . - Arm II : Patients receive CHOP chemotherapy arm I gemcitabine IV 30 minute day 1 8 . In arm , treatment repeat every 3 week 3 course absence unacceptable toxicity progressive disease . Patients achieve partial response complete unconfirmed complete response receive additional 5 course therapy ( total 8 course ) . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 76-82 patient ( 38-41 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma ( NHL ) 1 follow WHO subtypes : Diffuse large B large cell lymphoma ( include clinical morphologic variant ) Grade 3 follicular lymphoma Extranodal T/NK cell lymphoma , nasal type Enteropathytype T cell lymphoma Hepatosplenic T cell lymphoma Peripheral T cell lymphoma , unspecified Angioimmunoblastic lymphoma Anaplastic large cell lymphoma , systemic type Stage IIIV disease At least 1 site measurable disease ( e.g. , lymph node lymph node mass ) The following subtypes allow : Mantle cell lymphoma Burkitt 's lymphoma Precursor B T cell lymphoma Primary cutaneous B T cell lymphoma No CNS involvement lymphoma PATIENT CHARACTERISTICS : Age 18 70 Performance status Not specify Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 2.5 time normal ( unless due lymphoma ) ALT AST &lt; 2.5 time normal ( unless due lymphoma ) Renal Creatinine &lt; 2.0 mg/dL Cardiovascular No severe cardiac disease would preclude study participation limit life expectancy Pulmonary FEV_1 DLCO â‰¥ 75 % predict ( unless due lymphoma ) No severe pulmonary disease would preclude study participation limit life expectancy Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No severe neurologic metabolic disease would preclude study participation limit life expectancy No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent monoclonal antibody Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy No concurrent radiotherapy Surgery Not specify Other No prior cytotoxic agent No prior treatment NHL No concurrent anticancer therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>